ライフサイエンスコーパス: systemic vasculitis

1 granulomatosis with polyangiitis, a form of systemic vasculitis.

2 se features and treatments of these forms of systemic vasculitis.

3 e, and tolerable therapies for children with systemic vasculitis.

4 recommendations in the management of primary systemic vasculitis.

5 ease should be integral to the management of systemic vasculitis.

6 vascular morbidity for children with primary systemic vasculitis.

7 in finding other therapies to treat primary systemic vasculitis.

8 tis is defined within the context of primary systemic vasculitis.

9 the use of biologic agents as treatments for systemic vasculitis.

10 of endothelial injury during ANCA-associated systemic vasculitis.

11 i-neutrophil cytoplasmic antibody-associated systemic vasculitis.

12 (ANCA) are implicated in the pathogenesis of systemic vasculitis.

13 e response from tolerance to autoimmunity in systemic vasculitis.

14 (ANCA) are implicated in the pathogenesis of systemic vasculitis.

15 play an important role in clinical trials of systemic vasculitis.

16 dels have been proposed for various forms of systemic vasculitis.

17 of morbidity and mortality in patients with systemic vasculitis.

18 arious infectious syndromes in patients with systemic vasculitis.

19 und in the circulation of many patients with systemic vasculitis.

20 rkedly improved the outcome in patients with systemic vasculitis.

21 sa (PAN) has been used as a generic term for systemic vasculitis.

22 t not the ACR criteria for any other type of systemic vasculitis.

23 mune disorders (1.32; 95% CI, 1.16-1.50) and systemic vasculitis (1.29; 95% CI, 1.16-1.44).

24 ), systemic autoimmune disorders (7472), and systemic vasculitis (6283) and in 373 851 matched contro

25 tineutrophil cytoplasmic antibody-associated systemic vasculitis (AASV) as a model of systemic inflam

26 i-neutrophil cytoplasmic antibody-associated systemic vasculitis (AASV) as a model of systemic inflam

27 trophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) remain limited and hampered b

28 tineutrophil cytoplasmic antibody-associated systemic vasculitis (AASV), a disease not associated wit

29 They are common in patients with primary systemic vasculitis and are seen in vasculitis secondary

30 teinase-3 (PR3) antibodies in development of systemic vasculitis and granulomatosis with polyangiitis

31 periodontitis, inflammatory bowel diseases, systemic vasculitis and HIV infection, as well as chemot

32 tant role in vascular injury associated with systemic vasculitis and in models of autoantibody- and i

33 rats induced marked autoantibody production, systemic vasculitis and lymphocytic infiltration of the

34 in 88% of patients with antibody-associated systemic vasculitis and permitted reduction in steroid d

35 tinguish it from atherosclerotic AAA or from systemic vasculitis and to treat it with the appropriate

36 of agents commonly used in the treatment of systemic vasculitis, and 2) a framework for the diagnost

37 n important complication of several forms of systemic vasculitis, and it may result in significant mo

38 Autoimmune rheumatic diseases may present as systemic vasculitis, and systemic vasculitis may simulat

39 of this activity have long been attempted in systemic vasculitis, and, more recently, in atherosclero

40 cent developments in the nosology of primary systemic vasculitis are placed in the context of an hist

41 Systemic vasculitis associated with autoantibodies to ne

42 tion of hepatitis C virus (HCV) infection is systemic vasculitis associated with type II cryoglobulin

43 The study cohort comprised 39 children with systemic vasculitis at various stages of disease activit

44 to an unselected cohort of 130 patients with systemic vasculitis attending a single district hospital

45 scopic polyangiitis is a subgroup of primary systemic vasculitis, but diagnostic problems remain with

46 tis, are the connective tissue disorders and systemic vasculitis, but systemic infections and maligna

47 e-phase reactant levels in the patients with systemic vasculitis, but there was a poor correlation ov

48 ents with a new diagnosis of ANCA-associated systemic vasculitis confirmed by renal biopsy and serum

49 Plasma from patients with active systemic vasculitis contained significantly higher numbe

50 e specific factors involved in thrombosis in systemic vasculitis could help explain the role of infla

51 is affecting the nervous system includes (1) Systemic vasculitis disorders (necrotizing arteritis of

52 expression on neutrophils from patients with systemic vasculitis, Fc gammaRIIIb is likely to play a c

53 Patients with clinically active SLE or systemic vasculitis had accelerated spontaneous death of

54 ments in the classification and treatment of systemic vasculitis have led the European League Against

55 Temporal arteritis, the most common form of systemic vasculitis in adults, is a panarteritis that ch

56 ell arteritis (GCA), the most common form of systemic vasculitis in adults, preferentially involves l

57 ayasu arteritis) are the most common form of systemic vasculitis in adults, they remain incompletely

58 iant cell arteritis (GCA) is the most common systemic vasculitis in elderly individuals.

59 VDI scores for 100 patients with systemic vasculitis increased from initial presentation

60 Assessment of systemic vasculitis is an essential part of its manageme

61 ience with these agents for the treatment of systemic vasculitis is with antitumor necrosis factor ag

62 Current biomarkers of renal disease in systemic vasculitis lack predictive value and are insens

63 ry information suggesting that the impact of systemic vasculitis may be significant and far greater t

64 AECA in patients with SLE or systemic vasculitis may contribute to pathogenesis by in

65 ases may present as systemic vasculitis, and systemic vasculitis may simulate autoimmune rheumatic di

66 necrosis in the absence of overt evidence of systemic vasculitis, occurred in 3 patients.

67 och Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting wi

68 Kawasaki disease is an acute systemic vasculitis of childhood.

69 Kawasaki disease is a systemic vasculitis of childhood; its etiology is unknow

70 Kawasaki disease (KD) is a self-limited, systemic vasculitis of children for which an infectious

71 Wegener's granulomatosis (WG) is a systemic vasculitis of unknown etiology.

72 upus erythematosus (SLE) and 4 patients with systemic vasculitis on the expression of adhesion molecu

73 bsence of clinical or laboratory evidence of systemic vasculitis or a condition predisposing to such,

74 sitive SLE patients and 3 of 3 AECA-positive systemic vasculitis patients up-regulated adhesion molec

75 Giant cell arteritis (GCA) is a systemic vasculitis preferentially affecting large and m

76 ng non-systemic vasculitic neuropathy have a systemic vasculitis presenting with neuropathy; in other

77 of disease activity in children with primary systemic vasculitis (PSV).

78 27 SLE patients, three patients with systemic vasculitis, seven patients with arthritis, and

79 Systemic vasculitis should be further classified into on

80 erived from the largest genetic study of any systemic vasculitis, suggest a central role of CCR5-CCL3

81 interest in atherosclerosis, but less so in systemic vasculitis (SV).

82 by circulating cryoglobulin associated with systemic vasculitis symptoms.

83 l arteritis (GCA) is the most common form of systemic vasculitis that causes visual loss in the elder

84 he rate of renal recovery in ANCA-associated systemic vasculitis that presented with renal failure wh

85 For 100 surviving patients with systemic vasculitis, the median VDI score at last observ

86 ally based assessment of disease activity in systemic vasculitis, the Vasculitis Integrated Assessmen

87 icroparticle (PMP) profiles in children with systemic vasculitis to test the hypothesis that EMPs may

88 e 1990 ACR criteria and CHCC definitions for systemic vasculitis were applied to an unselected cohort

89 of tolerance to neutrophil components during systemic vasculitis, which is marked by autoantibodies a

90 Behcet disease (BD) is a systemic vasculitis with a broad range of organ involvem

91 lomatosis with polyangiitis (EGPA) is a rare systemic vasculitis with a prevalence rate of seven per